Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: PeterR1700 who wrote (17607)	3/18/1998 11:49:00 AM
From: Mudcat	Read Replies (4) \| Respond to of 32384

I also do not see why this leptin deal is a good deal for LGND. It is just another deal that dilutes the stock. All Lgnd receives is a 20% premium while issuing more shares. If you believe Henry's estimate for Lgnd of $30 a share by August, it appears Ligand is giving their technology away and SmithKline will more than pay for the research by selling their shares in Lgnd. I'm also not sure why Lgnd would make this deal now and not wait till the share price is higher (possibly after NDA filings). Guess even Lgnd management doesn't believe their stock will go much higher. Also what happens to Lgnd's share price when these drug companies start selling all these shares they are accumulating?